Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.

Nature communications - 24 Apr 2024

Li Jiang-Jiang, Yu Tiantian, Zeng Peiting, Tian Jingyu, Liu Panpan, Qiao Shuang, Wen Shijun, Hu Yumin, Liu Qiao, Lu Wenhua, Zhang Hui, Huang Peng

Abstract excerpt

Mutations in isocitrate dehydrogenases (IDH) are oncogenic events due to the generation of oncogenic metabolite 2-hydroxyglutarate. However, the role of wild-type IDH in cancer development remains elusive. Here we show that wild-type IDH2 is highly expressed in triple negative breast cancer (TNBC) cells and promotes their proliferation in vitro and tumor growth in vivo. Genetic silencing or pharmacological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Citric Acid Cycle
Share to Glutamine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycolysis

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Isocitrate Dehydrogenase

Share to Ketoglutaric Acids

Share to Triple Negative Breast Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38658533
DOI: 10.1038/s41467-024-47536-6
PMCID: PMC11043430

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.PMID 38658533Read ↗

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesSemantic proximity Read ↗

Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.Semantic proximity Read ↗

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human CancerSemantic proximity Read ↗

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancerSemantic proximity Read ↗

Cancer cells are sensitive to wild-type IDH1 inhibition under nutrient limitationSemantic proximity Read ↗

Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1α axis.Semantic proximity Read ↗

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells.Semantic proximity Read ↗

Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.Semantic proximity Read ↗

Targeting cancer metabolism.Semantic proximity Read ↗

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.